Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Operating Leases (2018 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Operating Leases for 8 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 23.43% to $8.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.5 million through Dec 2025, down 23.43% year-over-year, with the annual reading at $8.5 million for FY2025, 23.43% down from the prior year.
  • Operating Leases for Q4 2025 was $8.5 million at Cartesian Therapeutics, down from $8.7 million in the prior quarter.
  • The five-year high for Operating Leases was $14.1 million in Q1 2025, with the low at $3.2 million in Q4 2022.
  • Average Operating Leases over 5 years is $9.9 million, with a median of $9.7 million recorded in 2021.
  • The sharpest move saw Operating Leases crashed 62.78% in 2022, then skyrocketed 174.66% in 2023.
  • Over 5 years, Operating Leases stood at $8.6 million in 2021, then plummeted by 62.78% to $3.2 million in 2022, then surged by 174.66% to $8.8 million in 2023, then grew by 26.67% to $11.1 million in 2024, then fell by 23.43% to $8.5 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $8.5 million, $8.7 million, and $9.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.